Oral oseltamivir in human experimental influenza B infection.
about
A 'small-world-like' model for comparing interventions aimed at preventing and controlling influenza pandemicsSystematic review of influenza resistance to the neuraminidase inhibitorsEntry of parainfluenza virus into cells as a target for interrupting childhood respiratory diseaseNeuraminidase inhibitors for influenza B virus infection: efficacy and resistanceComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trialOseltamivir in human avian influenza infection.The role of facemasks and hand hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009-2011.Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.The potential for a controlled human infection platform in Singapore.Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge ModelRestoring invisible and abandoned trials: a call for people to publish the findings.Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.Subclinical avian influenza A(H5N1) virus infection in human, Vietnam.Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.Health-seeking behavior and transmission dynamics in the control of influenza infection among different age groups.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Influenza
P2860
Q21245278-CA872B32-A37E-41CF-9DE6-21A8A2D6E114Q21261835-1E063DF7-0CF9-4C6D-AF6E-8B7C2EBC0FBAQ24530163-D1BB82C7-6FDD-4554-AF9F-841A503C7687Q27021579-4E12A9C0-2A4B-4A61-A7E9-D777CB8966D1Q28364114-54DD43BC-814E-4161-9EBF-D47C2C346986Q28684866-8A277820-BDA6-4F40-8C6A-45DE8F2C9E2FQ30386487-1C6ED1AD-EBAC-4386-AABA-3B936F1A6BC2Q30412237-63BDD2A3-6955-4E04-A8C9-2DA8D651163BQ30424769-64DB749B-5D33-46D3-84AC-8203429E9AE3Q30625335-1FE3486C-DF39-4434-9108-D78BC488767EQ34952265-107BC7D4-F01A-4E24-B482-3A9AAC883FB0Q35127236-67C69F83-8FE3-4278-9E6A-AF2057CD6BFFQ35892839-B7875013-9FA4-48F8-A7EB-51D99E88BBD9Q36937327-1BB981A8-96D5-4E2A-A3BE-C4660FC33F1BQ37036527-B0E66409-39E4-4609-A18F-34FE0151FFE6Q37262016-EB5C4C5B-2C76-466F-9603-5AA6010D5A7CQ39671211-112457DA-9FF7-43BB-A10E-9DDFC4443135Q51783228-57CAAB6D-6C0A-4AD0-BBC6-F4A1C8029B06Q55447639-43ABE92A-7C19-4BB5-B343-5719AD5C1FDFQ56781494-39FC82B6-1F4D-484B-802E-3F6479E60E6B
P2860
Oral oseltamivir in human experimental influenza B infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Oral oseltamivir in human experimental influenza B infection.
@ast
Oral oseltamivir in human experimental influenza B infection.
@en
type
label
Oral oseltamivir in human experimental influenza B infection.
@ast
Oral oseltamivir in human experimental influenza B infection.
@en
prefLabel
Oral oseltamivir in human experimental influenza B infection.
@ast
Oral oseltamivir in human experimental influenza B infection.
@en
P2093
P1433
P1476
Oral oseltamivir in human experimental influenza B infection
@en
P2093
Jennings L
McClelland G
P304
P577
2000-09-01T00:00:00Z